Mira Pharmaceuticals Inc (MIRA)

MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders,...

MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...

MIRA Pharmaceuticals submitted an Investigational New Drug application to the FDA for Ketamir-2, its novel oral ketamine analog for neuropathic pain, marking a significant milestone in its mi

MIAMI, FLORIDA / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...

Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain

Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment

MIRA Pharmaceuticals' novel oral ketamine analog, Ketamir-2, has shown superior efficacy in reducing neuropathic pain compared to leading treatments like Gabapentin and Pregabalin, with the p

MIRA Pharmaceuticals' Ketamir-2 shows promise in treating neuropathic pain as a safer and more effective alternative to current medications, with potential applications in mental health as we

MIRA Pharmaceuticals has announced neuropathic pain as the primary indication for its new oral ketamine analog, Ketamir-2, offering a potential breakthrough in pain management.

U.S. stocks ticked lower and snapped an eight-day winning streak, the longest of the year